Par Pharma (PRX) Posts Q3 EPS of $0.76, Tops Views
More News related to PRX
- Par Pharmaceutical to Host Analyst Day on December 3rd
- Par Pharma (PRX) Receives Final U.S. FDA Approval for Tramadol ER Doses
- Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER
- Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Curren
- Par Pharma (PRX) Posts Q3 EPS of $0.76, Tops Views
More News related to Earnings
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
Par Pharmaceutical Companies, Inc. (NYSE: PRX) reports Q3 EPS of $0.76, versus the analyst estimate of $0.49. Revenue for the quarter was $294.80 million, which compares to the estimate of $290.44 million.
Related Categories
EarningsStocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
